United Therapeutics Corporation

Historical 13F Holders

Symbol
UTHR
CUSIP
91307C102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 91307C102 since 12/18/2024, largest first.

Filer % of Class Filed
Rothblatt Martine A 13G/A 5.3% 8/14/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.2% 4/30/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
State Street Corp 13G 4.9% 2/5/2025
Event 12/31/2024
Wellington Management Group LLP 13G/A
3.2% 8/13/2026
Event 6/30/2026
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 43 184 k $96.8 M
2026 Q2 911 75.1 M $22.7 B
2026 Q1 902 41.5 M $24.6 B
2025 Q4 869 42.2 M $20.5 B
2025 Q3 762 41.2 M $17.3 B
2025 Q2 703 44.1 M $12.7 B
2025 Q1 700 45.0 M $13.9 B
2024 Q4 707 44.3 M $15.6 B
2024 Q3 657 44.2 M $15.8 B
2024 Q2 605 47.1 M $15.0 B
2024 Q1 560 46.6 M $10.7 B
2023 Q4 558 45.5 M $10.0 B
2023 Q3 537 44.6 M $10.1 B
2023 Q2 502 45.1 M $9.94 B
2023 Q1 528 45.8 M $10.1 B
2022 Q4 535 46.6 M $13.0 B
2022 Q3 483 45.8 M $9.58 B
2022 Q2 493 44.2 M $10.4 B
2022 Q1 451 44.2 M $7.92 B
2021 Q4 440 43.3 M $9.37 B
2021 Q3 446 44.3 M $8.17 B
2021 Q2 422 44.2 M $7.93 B
2021 Q1 417 43.7 M $7.32 B
2020 Q4 386 44.2 M $6.72 B
2020 Q3 354 42.2 M $4.27 B
2020 Q2 376 42.6 M $5.15 B
2020 Q1 329 43.2 M $4.09 B
2019 Q4 344 41.9 M $3.69 B
2019 Q3 331 41.8 M $3.33 B
2019 Q2 356 42.2 M $3.29 B
2019 Q1 402 42.9 M $5.02 B
2018 Q4 380 44.1 M $4.78 B
2018 Q3 390 44.1 M $5.62 B
2018 Q2 397 42.9 M $4.85 B
2018 Q1 396 43.8 M $4.91 B
2017 Q4 422 44.6 M $6.56 B
2017 Q3 403 43.7 M $5.13 B
2017 Q2 399 46.3 M $6.01 B
2017 Q1 439 49.8 M $6.75 B
2016 Q4 436 48.0 M $6.88 B
2016 Q3 423 48.8 M $5.75 B
2016 Q2 414 49.6 M $5.25 B
2016 Q1 425 51.2 M $5.70 B
2015 Q4 416 51.6 M $8.08 B
2015 Q3 393 51.0 M $6.70 B
2015 Q2 410 51.0 M $8.87 B
2015 Q1 388 52.4 M $9.03 B
2014 Q4 351 51.6 M $6.69 B
2014 Q3 340 53.1 M $9.17 B
2014 Q2 317 53.6 M $4.75 B
2014 Q1 329 67.6 M $7.83 B